TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03135704

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Re Spine
Description: A new mattress design made of special materials and built in a specially shaped structure that allows the brain to relax the body and dissipate tension accumulated on the lumbar spine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Usual protocol for treatment of low back pain
Study: NCT04380337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Chemotherapy regimen of Oxaliplatin 85mg/m2, Leucovorin 400 mg/m2, 5-Fluorouracil 2400mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Chemotherapy regimen of Oxaliplatin 130 mg/m2, Capecitabine 1000mg/m2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Radiotherapy (5 Gy x 5 fractions) with an additional boost fraction (5 Gy x 1 fraction) delivered sequentially
Study: NCT01082146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: 40 mg suspension, PO, for 7 days
Study: NCT01865123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Description: A standard 7 step course will be offered including an introductory and preparatory lectures, personal one-on-one instruction with a certified TM teacher followed by 3 consecutive days of classes on how to meditate correctly and effortlessly, how to understand mechanisms of stress release and sequential development to higher levels of human consciousness and enjoying ones full potential. Followup meetings will provide checking of TM practice, sharing of group experiences with the TM practice and knowledge to motivate and inspire continued regularity with the practice. The certified TM instructor will have experience with PTSD in this veteran population.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: Prolonged exposure therapy, a specific form of cognitive behavioral therapy, is considered the standard psychotherapy treatment for PTSD . The delivery of PE will be by a trained study therapist. There will be 16 individual sessions provided to each participant. Homework will include relaxation and breathing exercises and anxiety diaries.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational control
Description: This group will receive group-administered didactic health education specific to the PTSD veterans population. It will include emphasis on healthy lifestyle changes to promote more positive mental and physical health. The classes will be matched with the TM and PE interventions to control for time, instructor attention and other non-specific factors.
Study: NCT02500875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTNiA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTNiB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTN
Study: NCT03084939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) was administered intravenously on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
Study: NCT02225821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalozin
Description: 1000 mg Cephalozin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: 10 cc of NaCl 0.9%
Study: NCT04282590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-750/Placebo
Description: Powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/TRK-750
Description: Powder for oral solution
Study: NCT01234766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90mg/m2, IV - Days 1 and 2 of every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Y-90 ibritumomab
Description: 0.4mCi/kg, IV - Within 4 hours of rituximab, give over 10 minutes
Study: NCT02495896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV
Study: NCT03918954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual sensory room
Description: A pair of virtual reality glasses (Oculus Go) with installed the program Calm Place, a program designed for anxiety reduction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensory room
Description: A room with calming elements that patients can use to feel calm.
Study: NCT01212406

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
Study: NCT02327819

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain amoni acids (BCAA)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: non-BCAA protein supplement
Study: NCT03399149

Intervention type: OTHER
Intervention: Systematic evaluation by an intensivist
Description: implementation of a standardized procedure for patient care in ICU
Study: NCT00641186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium oxybate
Description: 4.5 to 9.0 grams per night
Study: NCT01939782

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Breakfast (NoB)
Description: In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Breakfast (NoB)
Description: In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yes Breakfast (YesB)
Description: In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yes Breakfast (YesB)
Description: In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
Study: NCT03509792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple cognitive task
Description: A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention placebo
Description: Smartphone activity for same amount of time.
Study: NCT03331627

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STR001-IT and STR001-ER
Description: STR001-IT intrataympanic injection and STR001-ER tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STR001-IT and STR001-ER
Description: STR001-IT intrataympanic injection and STR001-ER tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STR001-IT and STR001-ER
Description: STR001-IT intrataympanic injection and STR001-ER tablet
Study: NCT03691285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Overdenture
Description: Placement of 1 or 2 implants in the anterior region of the edentulous mandible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Overdenture
Description: Placement of 1 or 2 implants in the anterior region of the edentulous mandible.
Study: NCT02071550

Intervention type: DEVICE
Intervention: FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor

Intervention type: DEVICE
Intervention: FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor

Intervention type: DEVICE
Intervention: FORESIGHT and INVOS monitor

Intervention type: DEVICE
Intervention: FORESIGHT and INVOS monitor
Study: NCT01235130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMEGA-3
Description: 600mg, 2 caps, twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soybean oil
Description: 600mg, 2caps twice a day
Study: NCT00798031

Intervention type: DEVICE
Group type: OTHER
Intervention: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.
Description: A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. The study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prosthesis.

Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of dental implant
Description: Device: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.~A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. the study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prothesis.

Intervention type: DEVICE
Group type: OTHER
Intervention: dental implant
Description: Subjects will have a complete diagnostic work-up performed and assessment for eligibility in the study by both a Prosthodontist and Surgeon. Subjects will then have two and up to three dental implants placed in an out patient basis at the University of Iowa College of Dentistry
Study: NCT05433896

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib ASD
Description: XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib ASD
Description: XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole 40 MG
Description: Omeprazole Delayed Release Capsules, USP 40 mg
Study: NCT03796013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib Form A
Description: Participants will receive a single oral dose of entrectinib form A under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib Form A
Description: Participants will receive a single oral dose of entrectinib form A under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib Form C
Description: Participants will receive a single oral dose of entrectinib form C under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib Form C
Description: Participants will receive a single oral dose of entrectinib form C under fasted conditions.
Study: NCT01213862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Education
Description: There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope, sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
Study: NCT04421937

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: Traditional Dysphagia Therapy (TDT)
Description: Traditional dysphagia therapy includes diet modification training, teaching postural compensatory methods, training of oral motor control exercises and tongue root exercises, training of swallowing maneuvers, and practice of chin-resistance exercise, which is the exercise of opening the upper esophageal sphincter.~Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procedure: Neuromuscular Electrical Stimulation with TDT
Description: The skin to be treated will be cleaned and dried. NMES will be implemented with signals received from two channels. In the first channel, the upper electrodes will be placed horizontally just above the hyoid bone. This is the place where the cupping is felt when the finger is pressed right under the chin. In the second channel, the lower electrodes will be placed horizontally, just above the thyrohyoid muscle. This is the place where you can feel a cupping when pressed with your finger, on both sides of the apple in the larynx. The device will be set to start at the lowest power, with very short pulses of approximately 700 microseconds, at intervals of 1 second. The power will be gradually increased according to the device and the power that the patient feels vibration will be stopped. The power to be applied will not exceed 25 milliamps. NMES application and Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks.
Study: NCT00991822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide 2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5%
Study: NCT04213586

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Description: 35 g of whey protein (7 d/wk) during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen supplementation
Description: 35 g of collagen (7 d/wk) + 2 g of leucine during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
Study: NCT00451568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg 2 tablets 2 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg 2 tablets 2 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desorelle
Description: 1 tablet/day in 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desorelle
Description: 1 tablet/day in 21 days
Study: NCT03066570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Exposure
Description: Graded Exposure in vivo (GEXP) is a second-generation cognitive-behavioural intervention, and is characterized by systematic and repeated exposure to feared movements, activities and/or sensations in order to decrease fear and subsequently increase physical activity.
Study: NCT00107744

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein-milk protein-carbohydrate
Description: 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk protein-carbohydrate-soy protein
Description: 40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-soy protein-milk protein
Description: 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks.
Study: NCT04366570

Intervention type: OTHER
Intervention: clinical assessment of the shoulder and the cervical spine includes stress guideline tests
Description: As a result of statistical processing, we are planning to obtain the most sensitive and specific tests from the clinical examination protocol

Intervention type: OTHER
Intervention: clinical assessment of the shoulder and the cervical spine includes stress guideline tests
Description: As a result of statistical processing, we are planning to obtain the most sensitive and specific tests from the clinical examination protocol

Intervention type: OTHER
Intervention: clinical assessment of the shoulder and the cervical spine includes stress guideline tests
Description: As a result of statistical processing, we are planning to obtain the most sensitive and specific tests from the clinical examination protocol
Study: NCT02758574

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CDT without ultrasound acceleration
Description: A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus a standard infusion catheter will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CDT with ultrasound acceleration
Description: A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus an infusion catheter that incorporates an ultrasound emitting wire will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus. The wire will be connected to an ultrasound generating device.
Study: NCT03625505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: tablet, oral
Study: NCT02359019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03609554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session). The Pilates programme was conducted by the Physical Education teacher, who was certified in Pilates training. The Pilates programme began at the basic level, incorporating more difficult principles and exercises gradually. The sessions were divided into the warm-up (7 min), the main part (41 min), and the cool down (7 min). Tt concentrated on basic Pilates exercises involving the principal regions of the body (spine flexions, extensions and rotations; hip flexions, extensions and rotations; and shoulder abductions, adductions and rotations).
Study: NCT02307747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: Blood samples will be collected every 4 hours during 24 h
Study: NCT04590859

Intervention type: PROCEDURE
Intervention: Block performed
Description: Comparing block performed with penile blood flow

Intervention type: PROCEDURE
Intervention: Block performed
Description: Comparing block performed with penile blood flow

Intervention type: DEVICE
Intervention: LMA placement
Description: Placement of LMA for airway securement

Intervention type: DEVICE
Intervention: LMA placement
Description: Placement of LMA for airway securement
Study: NCT02625194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen is supplied through suction port during bronchoscope-guided intubation.
Study: NCT03008720

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional electrical stimulation (FES)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation